📣 Connected drug discovery, united under one name. Discover the story behind our refreshed identity.

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Search Results

Search across news, resources and pages to quickly find relevant content on our site.

Loading…
News
BerGenBio granted a prestigious Wellcome Trust Seeding Drug Discovery Award
NOK 16 million awarded to develop novel cancer BerGenBio AS (“BerGenBio” or the “Company”), an…
News
Sygnature Discovery Celebrates 10 Years of Drug Discovery!
On Tuesday 7th October 2014 Sygnature Discovery celebrated its 10th anniversary by hosting a…
News
Aspects of Modern Drug Discovery: Insights from Leading Experts – Sygnature’s Symposium Speaker Summaries
The first guest speaker to take to the podium at Sygnature’s symposium on October 7th…
Journal Papers
A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs
M Redhead, R Satchell, V Morkūnaitė, D Swift, V Petrauskas, E Golding, S Onions, D Matulis, J Unitt Abstract Biophysical methods have emerged…
News
Sygnature’s Remarkable Export Growth Acknowledged in National League Table
Sygnature Discovery, has been listed in the inaugural Sunday Times BT Business SME Export Track…
News
Sygnature Discovery Careers Event – University of Oxford – 2nd June 2015, 6.30pm
Sygnature Discovery is holding a careers event at the University of Oxford: Date: Thursday 2nd June 2015…
News
Sygnature Discovery Successfully Provides Clinical Candidate to Corcept Therapeutics
Sygnature Discovery, a company which undertakes integrated drug discovery projects for pharmaceutical and biotechnology companies…
News
Sygnature Discovery Event for LATi Members | October 15, 2015
On the 15th October 2015, Sygnature Discovery will be hosting an event, entitled ‘A Global Reputation…
News
Scientific Journal Verifies Uniqueness of European Lead Factory’s Public Screening Collection
A scientific publication released this month in “Drug Discovery Today” details the results of a…
News
Sygnature Discovery Invests in Promising Startup, Peak Proteins
Sygnature Discovery, the UK’s largest independent provider of drug discovery expertise has invested, through…
News
Sygnature Discovery delivers over 21K novel compounds to the European Lead Factory, one of the top performing SMEs in the consortium
Sygnature Discovery has announced that is has delivered in excess of 21,000 novel chemical compounds…
News
Sygnature Discovery fournit plus de 21 000 nouveaux composés à l’European Lead Factory, l’une des PME les plus performantes du consortium.
Sygnature Discovery a annoncé avoir livré plus de 21 000 nouveaux composés chimiques à la…
News
Sygnature Discovery’s 2016 Expansion: Two Key Appointments Made
Dr Stephen Young has been appointed as Vice-President, Business Development, joining from Chinese CRO start-up,…
News
The Adoption of IncuCyte® ZOOM enhances Sygnature Discovery’s Capabilities
Sygnature Discovery Limited, a company which undertakes integrated drug discovery projects for pharmaceutical and…
News
Topping-out Ceremony For Sygnature’s New Discovery Building
A Landmark Achievement in Scientific Innovation and Growth Achieving a remarkable milestone, the…
News
Sygnature Discovery’s 2nd Year Success: ‘The Sunday Times Heathrow SME Export Track 100
We are delighted to announce that Sygnature Discovery has been placed No 65 in …
News
Dr Simon Hirst wins RSC’s Entrepreneur of the Year Award 2016
Dr Simon Hirst, Founder and CEO of Sygnature Discovery Limited, was tonight declared the winner…
News
Integration of the ImageXpress® Micro Confocal High-Content Imaging System
Sygnature Discovery Limited, a global provider of integrated drug discovery services, has announced the integration…
News
Sygnature Discovery Invests in New Technologies with £190K N2 Business Growth Fund Grant
Sygnature Discovery is set for further growth after receiving a £190,000 grant from the …
News
Sygnature Discovery’s drug discovery capabilities enhanced by acquisition of BMG LABTECH PHERAstar® FSX
Sygnature Discovery Limited, the UK’s largest independent provider of integrated drug discovery resource and…
News
The Corona sculpture starts to take shape on the new ‘Discovery’ building
Sygnature Discovery today saw the start of the Brise Soleil installation on the front of…
Load More

Support

Can't find what you're looking for?

Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.

Get in touch